Related Experiment Video
Updated: Apr 3, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Emerging agents for the therapy of advanced prostate cancer
Amanda R Hathaway1, Mary Katherine Baker1, Guru Sonpavde1
1University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL, USA.
Abstract:
Since 2010, multiple advances have been made in the field of metastatic castration-resistant prostate cancer including regulatory approvals for five new agents including androgen pathway inhibitors (enzalutamide, abiraterone acetate), immunotherapy (sipuleucel-T), cytotoxic chemotherapy (cabazitaxel) and radiopharmaceuticals (radium-223) that have improved overall survival in this patient population. Despite these advances, each therapy has only extended median survival by 3-5 months and data suggest substantial cross-resistance among them. Given these modest increments, there is a major role for the vigorous investigation of new drugs and predictive biomarkers to select suitable patients who will benefit from them. This review describes emerging promising agents and their ongoing clinical development.
Insights
Advances in metastatic castration-resistant prostate cancer treatments offer modest survival benefits. New drug investigations and predictive biomarkers are crucial for improving outcomes in this patient population.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) has seen significant therapeutic advances since 2010.
- Approved agents include androgen pathway inhibitors, immunotherapy, chemotherapy, and radiopharmaceuticals, improving overall survival.
Purpose of the Study:
- To review emerging promising agents for mCRPC.
- To discuss ongoing clinical development and the need for predictive biomarkers.
Main Methods:
- Literature review of recent advances in mCRPC treatment.
- Analysis of clinical development for novel therapeutic agents.
Main Results:
- Current mCRPC therapies provide limited median survival benefits (3-5 months).
- Substantial cross-resistance exists among existing treatment modalities.
- New drug development and biomarker identification are essential.
Conclusions:
- Despite advances, modest survival gains necessitate further research in mCRPC.
- Investigating novel agents and predictive biomarkers is critical for patient selection and improved outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...